Shanghai Bao Pharma Sets 28 Aug 2026 Board Meeting to Review H1 Results

Bulletin Express

Aug 18

Shanghai Bao Pharmaceuticals Co., Ltd. announced that its Board of Directors will convene on Friday, 28 August 2026. The meeting’s primary agenda is to review and approve the interim financial results for the six months ended 30 June 2026 and authorize their subsequent publication. Additional matters may also be considered during the session.

The Board is currently composed of Executive Directors Dr. Liu Yanjun (Chairman), Ms. Wang Zheng and Ms. Li Cui; Employee Representative Director Mr. Sun Yuhua; Non-Executive Directors Ms. Lin Chia-ling, Mr. Diao Juanhuan and Mr. Li Chen; and Independent Non-Executive Directors Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen and Mr. Zhang Senquan.

The company released the notice from its Shanghai headquarters on 18 August 2026, underscoring procedural transparency ahead of its mid-year earnings disclosure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1171121109"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171121109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171121109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171121109","market":"us","top_or_hot":-1,"title":"Shanghai Bao Pharma Sets 28 Aug 2026 Board Meeting to Review H1 Results","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. announced that its Board of Directors will convene on Friday, 28 August 2026. The meeting’s primary agenda is to review and approve the interim financial results for the six months ended 30 June 2026 and authorize their subsequent publication. Additional matters may also be considered during the session.</p>\n<p>The Board is currently composed of Executive Directors Dr. Liu Yanjun (Chairman), Ms. Wang Zheng and Ms. Li Cui; Employee Representative Director Mr. Sun Yuhua; Non-Executive Directors Ms. Lin Chia-ling, Mr. Diao Juanhuan and Mr. Li Chen; and Independent Non-Executive Directors Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen and Mr. Zhang Senquan.</p>\n<p>The company released the notice from its Shanghai headquarters on 18 August 2026, underscoring procedural transparency ahead of its mid-year earnings disclosure.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Bao Pharma Sets 28 Aug 2026 Board Meeting to Review H1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Bao Pharma Sets 28 Aug 2026 Board Meeting to Review H1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-18 16:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. announced that its Board of Directors will convene on Friday, 28 August 2026. The meeting’s primary agenda is to review and approve the interim financial results for the six months ended 30 June 2026 and authorize their subsequent publication. Additional matters may also be considered during the session.</p>\n<p>The Board is currently composed of Executive Directors Dr. Liu Yanjun (Chairman), Ms. Wang Zheng and Ms. Li Cui; Employee Representative Director Mr. Sun Yuhua; Non-Executive Directors Ms. Lin Chia-ling, Mr. Diao Juanhuan and Mr. Li Chen; and Independent Non-Executive Directors Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen and Mr. Zhang Senquan.</p>\n<p>The company released the notice from its Shanghai headquarters on 18 August 2026, underscoring procedural transparency ahead of its mid-year earnings disclosure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1171121109","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171121109","pubTimestamp":1787042895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. announced that its Board of Directors will convene on Friday, 28 August 2026. The meeting’s primary agenda is to review and approve the interim financial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"上海宝医药定于 2026 年 8 月 28 日召开董事会审查上半年业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. announced that its Board of Directors will convene on Friday, 28 August 2026. The meeting’s primary agenda is to review and approve the interim financial results for the six months ended 30 June 2026 and authorize their subsequent publication. Additional matters may also be considered during the session.\nThe Board is currently composed of Executive Directors Dr. Liu Yanjun (Chairman), Ms. Wang Zheng and Ms. Li Cui; Employee Representative Director Mr. Sun Yuhua; Non-Executive Directors Ms. Lin Chia-ling, Mr. Diao Juanhuan and Mr. Li Chen; and Independent Non-Executive Directors Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen and Mr. Zhang Senquan.\nThe company released the notice from its Shanghai headquarters on 18 August 2026, underscoring procedural transparency ahead of its mid-year earnings disclosure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}